R
8.77
0.77 (9.63%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Replimune Group, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.0
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -4.0 |
| 平均 | 0.00 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.61% |
| 机构持股比例 | 101.93% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sofinnova Investments, Inc. | 31 Dec 2024 | 3,149,522 |
| Omega Fund Management, Llc | 31 Dec 2024 | 1,975,203 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 22.00 (HC Wainwright & Co., 151.00%) | 购买 |
| 中 | 20.00 (128.18%) | |
| 低 | 18.00 (JP Morgan, 105.36%) | 购买 |
| 平均值 | 20.00 (128.18%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 13.77 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 26 Feb 2025 | 18.00 (105.36%) | 购买 | 13.24 |
| HC Wainwright & Co. | 13 Feb 2025 | 22.00 (151.00%) | 购买 | 14.29 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合